gut microbiome diet

Ultra-Processed Foods and the Cardiovascular-Kidney-Metabolic Continuum: Integrating Epidemiological, Multi-Omics, and Translational Evidence

25 March 2026

Singar S, Kachouei AA, Lantigua-Somoano L, Manley D, Cardinale A, Sadikan MZ, Kadyan S, Shahamati D, Dias L, Wood A, Chavarria C, Rosenkranz SK, Akhavan NS.

Summary

This research highlights that ultra-processed foods drive a "syndrome" of interconnected health issues, including obesity, kidney impairment, and heart disease. By analyzing biological markers, the study confirms that UPFs trigger systemic inflammation and metabolic stress, accelerating the progression from minor weight gain to serious clinical events.

Key Findings

Systemic Risk: Higher UPF intake is consistently linked to increased risks of adiposity (body fat), type 2 diabetes, chronic kidney disease, and cardiovascular mortality.
Biological Pathways: Advanced "omics" data show that UPFs damage health through chronic inflammation, lipid metabolism disruption, and intestinal barrier dysfunction (leaky gut).
Beyond Nutrients: The harm from UPFs isn’t just about high sugar or salt; it also stems from food additives, processing-induced compounds, and contaminants from packaging.
The CKM Continuum: The study promotes a unified view of health, showing how UPF-driven metabolic dysfunction in one organ (like the kidneys) directly worsens others (like the heart).

Practical Takeaways

Prioritize Food Quality: Focus on the degree of processing, not just calories. The additives and structural changes in UPFs can harm your metabolism regardless of the "macros."
Protect Your Gut: Because UPFs disrupt the gut barrier, emphasize fiber-rich whole foods to mitigate inflammation.
Early Intervention: Addressing UPF intake early can prevent the "staged" progression from metabolic dysfunction to irreversible organ damage.

Study Limitations

The review notes that accurately measuring UPF intake is difficult due to "brand heterogeneity" and participant under-reporting. Furthermore, more research is needed to isolate which specific additives or processing methods are the most toxic.

Abstract

Cardiovascular-kidney-metabolic (CKM) syndrome integrates excess adiposity, metabolic dysfunction, kidney impairment, subclinical cardiovascular diseases, and clinical events along a staged continuum that invites unified prevention and treatment. Ultra-processed foods (UPFs) are a complex, high-prevalence exposure that may influence risk across CKM stages through nutrient profiles, additives, processing-induced compounds, and packaging-related contaminants. This review synthesizes epidemiologic, mechanistic, and translational evidence with attention to exposure definition and analytic rigor. We summarize NOVA-based UPF operationalization across dietary assessment tools, highlighting misclassification of mixed dishes, brand heterogeneity, and energy under-reporting, and we propose further examination of energy-adjusted models, calibration, and harmonized metrics. Observational studies consistently associate higher UPF intake with adiposity, diabetes, chronic kidney disease, cardiovascular events, and mortality, with modest to moderate effect sizes that are heterogeneous across populations. Mechanistic data from metabolomics, lipidomics, proteomics, and the gut microbiome converge on pathways of inflammation, lipid metabolism, oxidative and metabolic stress, and intestinal barrier dysfunction; in selected cohorts, multi-omics modules account for a substantial minority of UPF-outcome associations. We outline quality-control pipelines, batch-effect prevention/correction, and multiple-testing control necessary for reproducible diet-omics. Translationally, targeted lipidomic and proteomic panels show promise for CKM risk stratification and monitoring but require validation, clinical thresholds, and guideline endorsement. Equity and global context, including differences in product mix, food systems, and care capacity, modify population impact. We conclude with a research agenda prioritizing harmonized exposure metrics, error-aware modeling, standardized multi-omics workflows, and adequately powered, stage-specific interventions capable of testing mediation and prognostic utility.

Source study →